News | December 12, 2007

WorldHeart Enters Strategic Alliance With Abiomed

December 13, 2007 - World Heart Corp., a developer of implantable mechanical circulatory support systems for chronic heart failure patients, announced its strategic alliance with Abiomed Inc., a leading manufacturer of devices for acute circulatory support.

WorldHeart and Abiomed currently serve complementary segments of the circulatory support market. This alliance is expected to benefit heart failure patients and treatment providers, promoting synergies between the two organizations in a number of areas, including:

- Products - WorldHeart's Novacor pulsatile LVAS and the Levacor Rotary VAD are designed to provide long-term support for chronic heart failure patients. Intended for use as a bridge to transplant or for destination (life-long) therapy, implant durations typically range from months to years. Abiomed markets a number of devices targeting primarily recovery applications,where support duration is measured in hours, days or months.The portfolios of the two companies collectively span the full spectrum of mechanical circulatory support needs, with implant durations ranging from hours to years, and from partial to total support.
- Clinical Relationships - The recipients of WorldHeart's chronic support devices are under the care of heart failure cardiologists and cardiac surgeons. Abiomed's products are administered by interventional cardiologists as well as cardiac surgeons.Collectively, the two companies have access to a broad base of clinical customers addressing a wide range of cardiac conditions.
- Marketing and Clinical Support - The two companies expect to be able to reach a broader customer base and provide an efficient and high level of clinical support.
- Technology - The companies also expect to explore opportunities for technology collaborations. The transcutaneous (across-the-skin) energy transfer system and implanted electronics developed for the AbioCor total heart potentially could be adapted to the Levacor, eliminating any wires through the skin to reduce the associated infection risk.

For more information: www. worldheart.com, www.abiomed.com

Related Content

Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist
Technology | Ventricular Assist Devices (VAD) | September 27, 2019
Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre...
CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD
News | Ventricular Assist Devices (VAD) | September 12, 2019
CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular...
Experts Caution Against Catch-all Assumptions About LVADs and Mitral Regurgitation

Paul Tang, M.D., Ph.D., a cardiac surgeon at Michigan Medicine’s Frankel Cardiovascular Center in the OR. Image courtesy of Michigan Medicine.

News | Ventricular Assist Devices (VAD) | August 20, 2019
Left ventricular assist devices (LVADs) have been shown to help leaky mitral valves that create significant...
FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Overlay Init